Husain Aliabbas A, Daginawala Hatim F, Singh Lokendra, Kashyap Rajpal S
Biochemistry Research Laboratory, Central India Institute of Medical Sciences, 88/2 Bajaj Nagar, Nagpur 440 010, India.
Biochemistry Research Laboratory, Central India Institute of Medical Sciences, 88/2 Bajaj Nagar, Nagpur 440 010, India.
Tuberculosis (Edinb). 2016 May;98:149-58. doi: 10.1016/j.tube.2016.03.006. Epub 2016 Mar 26.
Tuberculosis (TB) continues to be a global epidemic, despite of the availability of Bacillus Calmette Guerin (BCG) vaccine for more than six decades. In an effort to eradicate TB, vaccinologist around the world have made considerable efforts to develop improved vaccine candidates, based on the understanding of BCG failure in developing world and immune response thought to be protective against TB. The present review represents a current perspective on TB vaccination research, including additional research strategies needed for increasing the efficacy of BCG, and for the development of new effective vaccines for high TB endemic regions.
尽管卡介苗(BCG)已问世六十多年,但结核病(TB)仍是一种全球流行病。为了根除结核病,世界各地的疫苗学家基于对卡介苗在发展中国家失效情况的了解以及被认为对结核病具有保护作用的免疫反应,做出了巨大努力来研发改良的候选疫苗。本综述阐述了结核病疫苗接种研究的当前观点,包括提高卡介苗效力以及为结核病高流行地区研发新型有效疫苗所需的其他研究策略。